Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
Saved in:
| Published in: | Lung Cancer: Targets and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2025
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1868552401079762944 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Lung Cancer: Targets and Therapy |
| description | |
| discipline_display | Respiratory Diseases |
| discipline_facet | Respiratory Diseases |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:58418 |
| institution | FRELIP |
| journal_source_facet | Lung Cancer: Targets and Therapy |
| last_indexed | 2026-06-20T21:19:56.163Z |
| publishDate | 2025 |
| publishDateSort | 2025 |
| record_format | rss_article |
| spellingShingle | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 Respiratory Diseases General Respiratory Diseases |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Respiratory Diseases General Respiratory Diseases |
| subject_facet | Respiratory Diseases General Respiratory Diseases |
| title | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_alt | Una revisión concisa de los inhibidores de MET aprobados (savolitinib, gumarontinib, vebreltinib, tepotinib, capmatinib) en China para NSCLC con mutación en el sitio de empalme del exón 14 de MET (METex14+) hacia 2025 Une revue concise des inhibiteurs de MET approuvés (savolitinib, gumarontinib, vebreltinib, tépotinib, capmatinib) en Chine pour le CBNPC avec mutation du site d'épissage de l'exon 14 de MET (METex14+) vers 2025 Uma Revisão Concisa dos Inibidores de MET Aprovados (Savolitinibe, Gumarontinibe, Vebreltinibe, Tepotinibe, Capmatinibe) na China para CPNPC com Mutação no Sítio de Splice do Éxon 14 do MET (METex14+) por Volta de 2025 |
| title_auth | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_es_txt | Una revisión concisa de los inhibidores de MET aprobados (savolitinib, gumarontinib, vebreltinib, tepotinib, capmatinib) en China para NSCLC con mutación en el sitio de empalme del exón 14 de MET (METex14+) hacia 2025 |
| title_fr_txt | Une revue concise des inhibiteurs de MET approuvés (savolitinib, gumarontinib, vebreltinib, tépotinib, capmatinib) en Chine pour le CBNPC avec mutation du site d'épissage de l'exon 14 de MET (METex14+) vers 2025 |
| title_full | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_fullStr | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_full_unstemmed | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_pt_txt | Uma Revisão Concisa dos Inibidores de MET Aprovados (Savolitinibe, Gumarontinibe, Vebreltinibe, Tepotinibe, Capmatinibe) na China para CPNPC com Mutação no Sítio de Splice do Éxon 14 do MET (METex14+) por Volta de 2025 |
| title_short | A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025 |
| title_sort | a concise review of the approved met tkis (savolitinib, gumarontinib, vebreltinib, tepotinib, capmatinib) in china for met exon 14 splice site mutated (metex14+) nsclc circa 2025 |
| topic | Respiratory Diseases General Respiratory Diseases |
| url | https://www.dovepress.com/a-concise-review-of-the-approved-met-tkis-savolitinib-gumarontinib-veb-peer-reviewed-fulltext-article-LCTT |